<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[avant Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/avant.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to avant]]></description>
	<s:counts start="0" returned="20" found="217" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Five best gigs]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4158/is_20081115/ai_n31016901]]></link>
		<description><![CDATA[TV on the Radio Wed   "There's a golden age comin' round..." TV tore Bush's US to pieces on the genius Dear Science album, so expect the brainy Brooklynites to twist art-rock into celebratory shapes here. Avant- noise, beats-fuelled pop-rockets and future soul-rock is their hipster-groovy business. Shepherd's Bush...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 15 Nov 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/brixton+plc..html"><![CDATA[Brixton Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/sun+microsystems+inc..html"><![CDATA[Sun Microsystems Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAVA</category>
		<category domain="tickers">JAVA</category>
	</item>
	<item>
		<title><![CDATA[AVANT Announces Vaccine Adjuvant Licenses with 3M]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_11/ai_n25494720]]></link>
		<description><![CDATA[Access to enabling TLR adjuvants to advance novel antibody-based vaccine platform]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 11 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/3m+co..html"><![CDATA[3M Co.]]></category>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MMM</category>
		<category domain="tickers">MMM</category>
	</item>
	<item>
		<title><![CDATA[3M Collaborates with AVANT on Vaccine Adjuvants]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_11/ai_n25495009]]></link>
		<description><![CDATA[ST. PAUL, Minn. -- 3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics). Under the agreement, 3M will provide its patented toll-like receptor TLR agonist compounds to Celldex for an undisclosed licensing fee, milestones and royalties.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 11 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/3m+co..html"><![CDATA[3M Co.]]></category>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MMM</category>
		<category domain="tickers">MMM</category>
	</item>
	<item>
		<title><![CDATA[Avant Premiere of "Say It in Russian" at Monte-Carlo Television a Smashing Success]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25498924]]></link>
		<description><![CDATA[Imperia Entertainment, Inc (PINKSHEETS: IMPN) announced that last night's special public screening of the feature film, "Say It in Russian" during the Monte-Carlo Television Festival was attended by approximately 300, including international journalists as well as the general public. A red carpet arrival greeted stars Rade Sherbedgia, Agata Gotova, and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 10 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/say+it.html"><![CDATA[SAY IT]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[NIH Initiates Phase 1 Safety Study of AVANT's Oral Combined Enterotoxigenic E. coli-Cholera Vaccine]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_4/ai_n25475555]]></link>
		<description><![CDATA[First Clinical Study of Innovative Combination Vaccine]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 04 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT CEO to Present at the Needham & Company Biotechnology & Medical Technology Conference]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_4/ai_n25475902]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the Seventh Annual Needham & Company, LLC Biotechnology & Medical Technology Conference at the New York Palace Hotel in New York City on...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 04 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_2/ai_n25471310]]></link>
		<description><![CDATA[Survival and Time-to-Progression Reported From Open-Label Phase II Studies  CHICAGO -- AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual Meeting of the American Society of Clinical Oncology ASCO for CDX-110, an investigational...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 02 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/asco+plc..html"><![CDATA[Asco Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[New Analyst Reports for AVANT IMMUNOTHERAPEUTICS, CANADIAN SOLAR INC, LIBERTY MEDIA HOLDING CORPORATION, and BED BATH AND BEYOND INC]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200806/ai_n25479577]]></link>
		<description><![CDATA[MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for AVANT...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 02 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/analyst+report.html"><![CDATA[analyst report]]></category>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[AVANT Reports First Quarter 2008 Financial Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_19/ai_n25435156]]></link>
		<description><![CDATA[Conference Call Tuesday, May 20 at 9:00 a.m. Eastern Time]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 19 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Dr. Una Ryan Departs AVANT Immunotherapeutics]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_14/ai_n25412002]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics (NASDAQ: AVAN) today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Over the last fifteen years, Dr. Ryan was instrumental in the development and partnering of multiple products, including Rotarix([R])--an oral vaccine partnered with GlaxoSmithKline and recently approved by the FDA...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT to Report First Quarter 2008 Financial Results on May 19, 2008]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_14/ai_n25428325]]></link>
		<description><![CDATA[Conference Call to Follow]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 May 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_16/ai_n25157160]]></link>
		<description><![CDATA[NEW YORK & NEEDHAM, Mass. -- Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today announced that they have entered into an agreement under which Pfizer will be granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 16 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Significant Tumor-Specific Immune Response Observed in AVANT's Phase 2 Trial Evaluating CDX-110 with Temozolomide for Treatment of Glioblastoma Multiforme]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_15/ai_n25155767]]></link>
		<description><![CDATA[- New Data Subject of Late-Breaking Presentation at American Association for Cancer Research Meeting -]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 15 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_1/ai_n24965656]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that the double-blind, placebo-controlled multi-center Phase 2 clinical trial of its typhoid fever vaccine candidate, Ty800, met all primary endpoints. The Phase 2 study was an out-patient, dose-ranging clinical trial in 183 healthy volunteers that evaluated two dose levels of...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/endpoint.html"><![CDATA[endpoint]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT to Report Fourth Quarter and Year-End Fiscal 2007 Financial Results on February 27, 2008]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_20/ai_n24268838]]></link>
		<description><![CDATA[- Conference Call to Follow -]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 20 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[MOTORING: RS6 Avant model]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qn4161/is_20080203/ai_n21227150]]></link>
		<description><![CDATA[AUDI have announced prices and specification for the new RS6 Avant model. The RS6 is a derivative of the A6 Avant estate but it has Quattro four-wheel-drive, a six-speed automatic and a five- litre twin-turbo V10 producing 580bhp which makes this the most powerful production car Audi has ever produced...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 03 Feb 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/audi+ag.html"><![CDATA[Audi AG]]></category>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT Appeals Delisting Notification From NASDAQ]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Jan_9/ai_n24227276]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that on January 8, 2008 it received a letter from The NASDAQ Stock Market indicating that AVANT had failed to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share for continued listing of AVANT's...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 09 Jan 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[AVANT Immunotherapeutics Achieves Immune Responses Against Cholera, Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral Combination Vaccine]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_5/ai_n27463872]]></link>
		<description><![CDATA[NEEDHAM, Mass. -- AVANT Immunotherapeutics (Nasdaq: AVAN) today reported preclinical data demonstrating positive immunogenicity and lack of immune interference for an experimental single-dose, oral vaccine combining protection from three of the most important causes of severe enteric diseases: typhoid fever, enterotoxigenic E. coli ETEC and cholera. The experimental, trivalent vaccine...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 05 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[AVANT's Oral Combined Enterotoxigenic E. coli-Cholera Vaccine to Enter Phase 1 Safety Study Funded by the NIH]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Nov_19/ai_n21107371]]></link>
		<description><![CDATA[-- First Clinical Study of Innovative Combination Vaccine --]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 19 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Language Learning Solutions Rebrands as Avant Assessment]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200711/ai_n21112030]]></link>
		<description><![CDATA[Language Learning Solutions  today unveiled a new corporate name,  Avant Assessment , and brand identity. The move is part of a broader strategy to position itself for growth in the burgeoning language assessment field. Avant designs, develops, delivers, scores and reports Web-based language assessments for the diverse needs...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 15 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avant.html"><![CDATA[Avant]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
